The effects of the chronic administration of the sigma ligand JO 1784 (igmesine) CRF-induced changes in some behavioural, immune, endocrine and neurotransmitter parameters were studied. In the elevated plus maze, CRF (1.0 µg i.c.v. daily × 5 days) induced a reduction in the number of entries and time spent on the open arms was significantly attenuated by the sigma ligand JO 1784 (3 mg/kg × 21 days) treatment. In the ‘open field’ apparatus, the CRF-induced increase in the locomotor activity was also reduced by JO 1784 administration. JO 1784 treatment did not alter the concentration of the biogenic amine transmitters in the hypothalamus, nor reverse the increase in the turnover of serotonin and dopamine caused by CRF. JO 1784 treatment also failed to reverse a CRF-induced increase in the serum corticosterone, but it did reverse the reduction in phytohaemagglutinin and concanavalin A-induced lymphocyte proliferation caused by CRF but not the changes in the lymphocyte and neutrophil numbers caused by the peptide. These results demonstrate that JO 1784 has some antistress properties in CRF-treated rats.

Keywords:
Sigma ligand JO 1784 CRF, Stress, Neurotransmitters, Behaviour, Cellular immunity
This content is only available via PDF.
© 1997 S. Karger AG, Basel
1997
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.